Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | AURKA | O14965 | 16/20 | 1.00 |
| ▸ | TEK | Q02763 | 16/20 | 1.00 |
| ▸ | MET | P08581 | 14/20 | 1.00 |
| ▸ | LCK | P06239 | 13/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.93 |
| ▸ | LYN | P07948 | 3/20 | 0.93 |
| ▸ | ABL1 | P00519 | 2/20 | 0.93 |
| ▸ | FGR | P09769 | 1/20 | 0.93 |
| ▸ | FLT1 | P17948 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548845 | 0.98 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL2746021 | 0.96 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL4548830 | 0.92 | KDR (0.88) | KDRAURKATEKMETLCK | |
| SCHEMBL4548837 | 0.89 | KDR (0.83) | KDRAURKATEKMETLCK | |
| SCHEMBL2746931 | 0.89 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL2746969 | 0.89 | KDR (0.86) | KDRAURKATEKMETLCK | |
| SCHEMBL2747800 | 0.88 | KDR (1.00) | KDRAURKATEKMETLCK | |
| SCHEMBL2097763 | 0.87 | KDR (0.83) | KDRAURKATEKMETLCK | |
| SCHEMBL2747093 | 0.87 | KDR (0.79) | KDRAURKATEKMETLCK | |
| SCHEMBL2747986 | 0.87 | KDR (0.79) | KDRAURKATEKMETLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885AURKA 4148/4885TEK 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.